Posted by Michael Wonder on 01 Nov 2020
FDA approves Bronchitol for US market
2 November 2020 - Pharmaxis to manufacture product and export to USA.
Pharmaceutical research company Pharmaxis today announced the United States FDA has approved Bronchitol (mannitol) as add‐on maintenance therapy to improve pulmonary function in cystic fibrosis patients 18 years of age and older.
The product, developed by Pharmaxis in Australia, has been steered through final stages of FDA approval by US licensee Chiesi.
